Patent US5082928A successfully refreshed from Google Patents.
US5082928A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of preparing conjugated antibodies
Assignee: Individual
•
Filing: 1989-11-13
•
Granted: 1992-01-21
•
Expires: 2009-11-13
Abstract
Abstract The present invention is directed to a method of preparing a conjugated antibody agent, and conjugated antibody agent obtained thereby. The method includes: (i) attaching a substantially pure antigen to a solid phase; (ii) passing an antibody containing composition over the solid phase such that the antibody is caused to bind to the attached antigen by immunoreaction to form a bound antigen-antibody complex; (iii) passing a reactive conjugating agent over the bound antigen-antibody complex to conjugate the conjugating agent to said complex; to (iv) removing the resultant conjugated antibody from the solid phase.
Inventors
- 👤 Mark P. Best
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 20:37
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/06; C07K16/065; Y; Y10; Y10S; Y10S436/00; Y10S436/804
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
73 words
A method of preparing a conjugated antibody comprising (i) attaching a substantially pure antigen to a solid phase; (ii) passing an antibody containing composition over said solid phase such that said antibody binds to said attached antigen to form a bound antigen-antibody complex; (iii) passing a reactive chelating agent over said bound antigen-antibody complex to chelating said conjugating agent to said complex; and (iv) removing the resultant conjugated antibody from said solid phase.
Claim 2
Independent Claim
73 words
A method of preparing a conjugated antibody comprising (i) attaching a substantially pure antigen to a solid phase; (ii) passing an antibody containing composition over said solid phase such that said antibody binds to said attached antigen to form a bound antigen-antibody complex; (iii) passing a reactive chelating agent over said bound antigen-antibody complex to chelating said conjugating agent to said complex; and (iv) removing the resultant conjugated antibody from said solid phase.
Claim 3
Independent Claim
47 words
A method of preparing a conjugated antibody comprising: (i) reacting a substantially pure antigen with an antibody to form a bond antigen-antibody complex; (ii) conjugating a reactive chelating agent with said bound antigen-antibody complex; and (iii) cleaving said antigen from said antibody to form a conjugated antibody.
Claim 4
Independent Claim
47 words
A method of preparing a conjugated antibody comprising: (i) reacting a substantially pure antigen with an antibody to form a bond antigen-antibody complex; (ii) conjugating a reactive chelating agent with said bound antigen-antibody complex; and (iii) cleaving said antigen from said antibody to form a conjugated antibody.
Claim 5
Independent Claim
189 words
A method of preparing a conjugated antibody comprising the steps of (I) (a) packing a solid phase in the column of a syringe; (b) washing said solid phase with 0.001M HCl; (c) coupling calcitonin HCO 3 - buffer for two hours at room temperature; (d) washing the column with HCO 3 - buffer; (e) reacting said beads with 1M ethanolamine at about pH 8; (f) washing said beads with 0.1M acetate buffer at about pH 4; (g) washing said beads with 0.1M borate buffer at about pH 8; (h) repeating said steps (f) and (g); (i) washing said column with an affinity antibody containing solution; (j) washing said column with phosphate buffered saline to form an immuno-adsorbent bead complex with said antibody; (II) conjugating said immuno-adsorbent bead complex with a chelating agent to form a conjugated antibody by (a) washing said column with an HCO 3 - buffer; (b) flushing said column with diethylamine triamine pentacetic acid anhydride; (c) washing said column with phosphate buffered saline; (d) eluting said antibody chelate conjugate with 6M guanidine HCl; and (III) separating said antibody conjugate from said guanidine HCl by gel filtration.
Claim 6
Independent Claim
189 words
A method of preparing a conjugated antibody comprising the steps of (I) (a) packing a solid phase in the column of a syringe; (b) washing said solid phase with 0.001M HCl; (c) coupling calcitonin HCO 3 - buffer for two hours at room temperature; (d) washing the column with HCO 3 - buffer; (e) reacting said beads with 1M ethanolamine at about pH 8; (f) washing said beads with 0.1M acetate buffer at about pH 4; (g) washing said beads with 0.1M borate buffer at about pH 8; (h) repeating said steps (f) and (g); (i) washing said column with an affinity antibody containing solution; (j) washing said column with phosphate buffered saline to form an immuno-adsorbent bead complex with said antibody; (II) conjugating said immuno-adsorbent bead complex with a chelating agent to form a conjugated antibody by (a) washing said column with an HCO 3 - buffer; (b) flushing said column with diethylamine triamine pentacetic acid anhydride; (c) washing said column with phosphate buffered saline; (d) eluting said antibody chelate conjugate with 6M guanidine HCl; and (III) separating said antibody conjugate from said guanidine HCl by gel filtration.
Claim 7
Dependent Claim
30 words
The method of claim 1 further comprising labelling said conjugated antibody with a labelling agent selected from the group consisting of a radio-labelling agent and a NMR scanning contrast agent.
Claim 8
Dependent Claim
22 words
The method of claim 1 further comprising labelling said conjugated antibody by mixing same with stannous chloride, lyophilizing and adding radio-labelling agent.
Claim 9
Dependent Claim
14 words
A method as claimed in claim 5 in which the radio-labelling agent is technetium.
Claim 10
Dependent Claim
34 words
A method of preparing site directed cytotoxic or therapeutic agents comprising the additional subsequent step of conjugating a cytotoxic or therapeutic agent with the conjugated antibody prepared according to the method of claim 1.
Claim 11
Dependent Claim
24 words
The method according to claim 7 wherein said therapeutic agent is selected from the group consisting of yttrium 90, palladium, methotrexate, ricin and iodine.
Claim 12
Dependent Claim
20 words
The method according to claim 7 wherein said cytotoxic agent is selected from the group consisting of methotrexate and ricin.
Claim 13
Dependent Claim
24 words
A method as claimed in claim 1 in which said chelating agent is selected from the group consisting of DTPA, iminodiacetic acid, and desferrioxamine.
Claim 14
Dependent Claim
16 words
A method as claimed in claim 1 in which said antigen is a tumour associated antigens.
References Cited (Backward Citations)
US4460559A
Cited
US4658022A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-20 | 1995-07-22 | 1996-01-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-20 | 1999-07-22 | 2000-01-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-20 | 2003-07-22 | 2004-01-21 | $7700.00 | Window Closed / Lapsed |